Call: (+91) 73979 11126
Brand Name : Kemocarb Composition : Carboplatin Strength : 150mg, 450mg ml Manufactured by : Fresenius Kabi India Pvt Ltd Form : Injection
Kemocarb Injection is used in the treatment of ovarian cancer and small cell lung cancer. It shows its working by stopping or slowing down the growth of cancer cells.
In Ovarian cancer Ovarian cancer is a cancer that begins in the female organs that produce eggs (ovaries). This type of cancer is usually detected very late and can be fatal too. It usually spreads to the pelvis and stomach. Kemocarb 150mg Injection kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective medicine but has some side effects that may be bothersome. So, you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated. In Small cell lung cancer Small cell lung cancer is a fast-growing type of lung cancer commonly caused by smoking that starts with small tumors in the lungs but eventually spreads to the other parts of the body as well. Kemocarb 150mg Injection helps treat such types of cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
Kemocarb Injection is an anti-cancer medication. It works by damaging the genetic material (DNA and RNA) of the cancer cells which stops their growth and multiplication.
Product Enquiry
Select you countryAfghanistanAlbaniaAlgeriaAndorraAngolaAntigua and BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanThe BahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCentral African RepublicChadChileChinaColombiaComorosCongoCosta RicaCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFijiFinlandFranceGabonThe GambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyamaicaJapanJordanKazakhstanKenyaKiribatiKorea, NorthKorea, SouthKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorth MacedoniaNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRussiaRwandaSaint Kitts and NevisSaint LuciaSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri LankaSudanSudan, SouthSurinameSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamYemenZambiaZimbabwe
Log in